SEER is an authoritative source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
Lymph nodes (C770-C779) are the usual primary sites; however, involvement in other sites is possible. If you have confirmation that the only involved site is something other than the lymph nodes, then code to that primary site. See Module 7.
Nodular sclerosis classical Hodgkin lymphoma (NSCHL) occurs in the mediastinum in 90% of the cases, bulky disease in 54%, splenic and/or lung involvement in 8-10%, bone involvement in 5%, bone marrow involvement in 3%, and liver involvement in 2%.
Most patients present with stage II disease. B symptoms are encountered in approximately 40% of cases. Massive mediastinal disease is an adverse prognostic disease.
For more information on this neoplasm, see the NCI website: http://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq or http://www.cancer.gov/types/lymphoma/patient/adult-hodgkin-treatment-pdq